News

The approval was based on data from the Phase 2 BLAST study in frontline and relapsed/refractory ALL, the largest prospective trial for MRD-positive ALL ever conducted. BLINCYTO, a

RP-A501 is the Company’s first adeno-associated viral vector (AAV)-based gene therapy for the treatment of Danon disease that is in development under a collaboration with the University of

Tesaro acquisition will enable GSK to strengthen its pharmaceutical business; and expand its pipeline and commercial capability in oncology. Tesaro president and COO Dr Mary Lynne Hedley said:

The label extension has been granted to treat the most common form of CF based on data from a phase 3 open-label safety study in 60 patients. According

In addition, a second compound, NP-135 was identified as an additional lead. Both NP-135 and NP-160 are one of a number of already approved compounds that Nash has

PCI has extended onsite controlled substance storage at its US commercial packaging locations in Philadelphia, PA and Rockford, IL, and will undertake further expansions as demand increases for

The RapidResponse platform has been selected for Novartis global TechOps organization, as part of a wider supply chain transformation initiative. RapidResponse is a cloud-based integrated supply chain planning platform,

Promentis is developing SXC-2023 along with other compounds that engage System xc-, a central nervous system target addressing glutamatergic imbalance and oxidative stress, to treat trichotillomania and other

The collaboration will combine the immuno-oncology expertise and pipeline of Kyn Therapeutics with the capabilities of Celgene in development and commercialization of drugs in areas of high unmet